Growth without growth hormone (GH) has occasionally been described in patients with organic pituitary pathology, and even more rarely in patients with idiopathic pituitary hormone deficiency. The mechanism of growth without GH remains a mystery. We describe a 17-year old male who grew 38.5 cm in height over a 7-year period, despite the fact that he had established panhypopituitarism. The hypopituitarism was initially attributed to a presumptive hypothalamic hamartoma which was not, however, confirmed on subsequent and prolonged follow-up. Regular endocrine evaluation confirmed persistent anterior and posterior pituitary hormonal deficiencies with severe concomitant hyperinsulinemia as shown by an exaggerated insulin response to a standard oral glucose tolerance test. In our patient, a postulated mechanism could be the severe hyperinsulinemia, acting either through the insulin and/or IGF receptors and thus potentiating the mitogenic effect. This case illustrates that final height attainment within or above target height may occur in patients with idiopathic pituitary hormonal deficiency despite persistent, severe GH insufficiency.
INTRODUCTION
Normal linear growth in children along the percentile of their genetic potential is a highly complex process, regulated by the interaction of genetic, nutritional, environmental and hormonal factors 1 . Among the various hormonal factors implicated, growth hormone (GH) plays a predominant role and influences the growth pattern throughout the growth period 2, 3 . Lack of GH is characterized mainly by growth retardation, short stature and by reduced growth spurt during puberty 4 . The vast majority of these abnormalities are restored with administration of GH 1 . Growth without GH is a rare but well-described phenomenon that was initially reported either following surgical interventions for suprasellar tumors, mainly craniopharyngiomas, or even without an organic cause 1, 5 . Obesity and hyperphagia, as well as the concomitant hyperinsulinemia or a synergistic action of the postsurgery hyperprolactinemia were initially implicated for the growth spurt in children with apparent GH deficiency (GHD) following surgery of the hypothalamo-pituitary system (HPS) 6, 7 . Later, the same phenomenon was observed in cases with empty sella syndrome 8 and septo-optic dysplasia 9 . In such cases, it has been hypothesized that potent growth factors [10] [11] [12] and GH variants 13 likely mimic the biologic activity of GH thus accounting for this phenomenon. Moreover, during priate for the chronological age of the patient. Further investigation revealed lower than the age-adjusted prolactin (PRL), insulin growth factor (IGF-I), and insulin growth factor binding protein 3 (IGFBP-3) levels. Gonadotropins, thyroid hormone, thyrotropin and basal cortisol as well as 17-hydroxyprogesterone and testosterone levels were within those predicted for his age limits (actual values are not available as all investigations were carried out in the Virchow -Klinikum Institution of Berlin, Germany). No further basal or dynamic investigations of the pituitary function were undertaken at that time. Magnetic resonance imaging (MRI) of the pituitary reportedly demonstrated a 10x8x6 mm hypothalamic mass that presented the radiological features of a hypothalamic hamartoma (original scans not available). The patient was discharged receiving intranasal desmopressin for the treatment of DI. When the patient was re-assessed at the same institution a year later, the clinical examination revealed stage 1 genital development (G1), stage 2 pubic hair (P2), a testicular volume of 2-3 ml, and a height of 152 cm. Endocrine investigation was consistent with central hypothyroidism [free thyroxine (FT4) fetal life, growth without GH is a normal condition possibly occurring through an interplay between fetal plasma insulin and IGF-I levels 14 .
We here in report a distinct growth pattern in a patient with idiopathic panhypopituitarism who has been followed for a 7-year period. The various associated clinical conditions and the proposed mechanisms for the paradox of growth in the absence of GH are also reviewed.
PATIENT REPORT
A 17-year old male was admitted for investigation of delayed puberty with a presumptive diagnosis of hypothalamic hamartoma. Hamartoma was originally suspected at the age of 10 years when the patient was examined following the acute onset of polyuria and polydipsia. The diagnosis of central diabetes insipidus (DI) was then made which subsequently responded to treatment with intranasal desmopressin (10-12 ìg daily). Clinical examination at that time revealed a rather overweight child (body weight of 52 kg, 93 rd percentile, Figure 1a ) with mainly truncal obesity. The height was 147cm (85 th percentile, Figure 1b) . Radiography of the left hand revealed a bone age of 11.5 years; the pubertal stage was considered appro- (Table 1) . Basal endocrine investigation revealed adequately replaced thyroid function with the presence of positive autoantibodies, hypogonadotrophic hypogonadism, low basal cortisol and IGF-I levels and very low sex hormone binding globulin (SHBG) levels (Table 2). The maximum GH response to insulin induced hypoglycemia was 0.1ìg/L, consistent with the diagnosis of GHD; in addition, a standard 75 g oral glucose tolerance test (OGTT) revealed normal glucose tolerance with concomitant severe hyperinsulinemia ( Table 2 ). There was no evidence of abnormal IGF-II or pro-IGF II molecules (analysis was performed by courtesy of St Bartholomews Hospital). Roentgeno-2.5pmol/L (normal range 9-26 pmol/L) and TSH 3.65 mU/L (normal range 0.5-5,0 mUL)] and the patient was given levothyroxine 100ìg/day. Further endocrine assessment revealed no GH response following the intravenous administration of growth hormone releasing hormone (GHRH) consistent with the diagnosis of GH deficiency, while the levels of both gonadotropins [follicle stimulating hormone (FSH) and luteinizing hormone (LH)] hormones were undetectable. No further dynamic endocrine tests were performed. A subsequent pituitary MRI revealed the previously noted hypothalamic lesion which had not changed in size. At the age of 13 years, the patient was re-evaluated at the same department. Clinical examination revealed a body weight of 76.5 kg and a height of 166 cm [body mass index (kg/m 2 ) BMI=27.8]; pubertal stage was still G1 and P2. Endocrinological investigation revealed IGF-I levels of 39 ìg/L (normal age adjusted levels 55-216 ìg/L) and IGFBP-3 levels of 2.18 mg/L (normal range 3-5.6 mg/L). The patient also underwent basal and dynamic endocrine investigation which revealed panhypopituitarism [inadequate GH and cortisol response to an insulin tolerance test (ITT), no TSH response to TRH, although PRL levels rose from 3.5 ng/mL to 7.5 ng/mL; LH and FSH levels rose to 2.3mU/ml, and 2.5mU/ml, respectively, following stimulation with GnRH]. A pituitary MRI was repeated, which, in contrast to the previously noted hypothalamic mass, revealed no abnormal findings. As this investigation was also performed at the same institution in Germany the scans are not available. Following the diagnosis of hypopituitarism, the patient was initiated on treatment with hydrocortisone 20 mg a.m. and 10 mg p.m., while the dose of levothyroxine was increased to 150ìg/day and he continued to receive intranasal desmopressin (10-12 ìg daily). No more data are available regarding either the patients possible adrenarche or the investigation of other metabolic actions of GH.
The patient was lost to follow-up and no validated data exist concerning the interim growth rate. Four years later, at the age of 17 years, he was admitted for the first time to our department due to lack of pubertal development and for re-evaluation of the previously noted hypothalamic lesion. On admission, he had a blood pressure of 100/60 mmHg. His height was 185.5 cm (predicted height:186,5 ±8 cm) and is expected to increase further since his bones are still open. He was noted to be overweight [body weight of 108 grams revealed a bone age of 14 years, whereas bone density showed osteopenia (t-score of -1.54). A pituitary MRI revealed a partially empty sella with pituitary compression and stalk atrophy but no evidence of the previously noted hypothalamic pathology (Figure 2) . No other evidence of GH deficiency was present, whereas an AGHDA (Adult Growth Hormone Deficiency Assessment) score was normal and did not reveal any alterations of the quality of life that could be attributed to GHD.
The diagnosis of panhypopituitarism was reconfirmed and the patient, in addition to his other pituitary hormonal deficiency replacement therapy, was also started on androgen replacement therapy with testosterone enanthate (testosterone initially 125 mg monthly and thereafter 250 mg every 20 days). Á calorie-restricted diet was also initiated while the decision for possible GH replacement treatment to ameliorate the dyslipidemic profile and improve the patients body composition (especially the abdominal accumulation of adipose tissue) was postponed for the follow-up period. Further growth in height is expected considering the fact that his epiphyses were still open during his last visit.
DISCUSSION
Traditionally, GH has been considered as a pre-throughout the growth period 1 . In some of these patients GH had to be administered to achieve a normal final height 1, 19 . Sustained and/or accelerated linear growth has also been reported not only after surgical intervention for craniopharyngiomas or other suprasellar lesions 1 but also in a number of other diseases and hypothalamic disorders 5, 20 and in association with some intracranial anomalies such as septo-optic dysplasia 1 . As most of these patients were obese, the concomitant hyperinsulinemia has again been implicated as a probable pathogenic mechanism [6] [7] [8] [9] [10] [11] [12] [13] 21 , although the presence of hyperprolactinemia and/or other bioavailable GH/ IGF-I variants have alternatively been suggested 5, 12 . However, it is unlikely that hyperprolactinemia could significantly affect the growth pattern 5 , even in cases following neurosurgical intervention where the prolactin levels remain mildly elevated 22, 23 . Also postulated is the presence of an unidentified growth factor that could influence chondrocyte proliferation through mechanisms other than GH 1 . In favour of this view is the finding of a recent study in which dissociation between the growth effects of GH or another factor maintaining growth and the GH-dependent metabolic effects was documented 21 . This finding also raises the issue of administering recombinant GH replacement in patients exhibiting growth without GH in order to correct the possible metabolic sequellae related to the lack of GH 20, 21 in these children.
Recently, elevated leptin levels were found in cases with normal growth rate and GH deficiency 1, 24 ; it was thus suggested that leptin might contribute to linear growth independent of GH by directly influencing the growth plate 1 since osteoblast cell proliferation was not confirmed in response to leptin 24 . However, the role of leptin as a regulatory signal of GH secretion remains to be identified 24 , especially in obese, GH deficient subjects following craniopharyngioma removal 25 since the correlation of leptin with obesity and body mass index is an otherwise adequately described phenomenon 24 . Additionally, growth without GH was also observed in a patient with deficiencies of GH, LH and FSH, and a hypoplastic pituitary due to a mutation in the PROP1 gene 26 .
In our patient, the obvious hypothalamic damage did not result from a neurosurgical procedure but could be related to the initially reported hypothalamic hamartoma. Although the latest pituitary MRI re- requisite for normal post-natal growth and for the achievement of a predicted final height. However, cases of normal growth without GH have previously been reported, particularly after surgery for craniopharyngioma [5] [6] [7] [15] [16] [17] [18] . The common finding in the majority of these cases was post-operative weight gain, which in some cases reached the point of morbid obesity. Obesity-induced hyperinsulinemia and/or the coexistence of hyperprolactinemia have been considered as possible pathogenic mechanisms 6, 7, 15, 18 . A few cases of sustained growth in patients with idiopathic combined pituitary deficiency have also been described 1 . Similarly, our patient, although exhibiting the clinical (obesity, abnormal body composition with accumulation of abdominal fat) and endocrinological (subnormal basal IGF-I and subnormal GH levels following insulin induced hypoglycemia) features of GH deficiency, achieved substantial growth and even exceeded the expected target height. Another unique finding of this case is the maintenance and even increase in growth rate that was sustained throughout the growth period. This is in contrast to patients who display growth without GH following brain surgery, in whom the GH-independent growth is not sustained vealed a partially empty sella with pituitary compression and stalk atrophy without any evidence of a hamartoma, we must assume that either there was a structural abnormality of the HPS resulting in anterior and posterior pituitary deficiency or that this could be related to a developmental defect. However, the possibility of hypothalamic damage is plausible as the patient developed obesity, probably because of increased appetite and hyperphagia as well as severe subsequent insulin resistance and hyperinsulinemia (Table 2) . Although the presence of other, unmeasured, growth promoting factors and/or other still unrecognized factors cannot be excluded in this case, the most contingent postulated mechanism for growth without GH is the severe hyperinsulinemia acting either through the insulin receptor potentiating its mitogenic effect and/ or directly affecting increasing IGF-I bioavailability.
In summary, this case illustrates that growth without GH can occur even in patients not undergoing a surgical intervention in the hypothalamo-pituitary area. Normal levels of circulating GH and/or IGF-I are not mandatory to maintain normal bone elongation. Although unknown growth factors with sufficient compensatory ability may be involved, the coexistent severe insulin resistance and compensatory hyperinsulinemia should always be investigated as insulin may be a direct stimulatory factor exerting such a mitogenic activity.
